← All trials
NCT07213804
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 22, 2025
- Primary completion
- Apr 30, 2028
- Completion date
- Aug 31, 2031
- First posted
- Oct 9, 2025
- Last posted
- Nov 21, 2025
- Enrollment
- 1080
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Eli LillyLead sponsor
- European Network for Gynaecological Oncological TrialCollaborator
- GOG Foundation, Inc.Collaborator
- Eli LillyOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.